MedTrace Logo

Biomarkers in Depressed Inpatients Receiving Accelerated rTMS

NCT03628573 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2020-12-01

No results posted yet for this study

Summary

Repetitive transcranial magnetic stimulation (rTMS) is an emerging treatment for medically refractory major depressive disorder (MDD), and involves direct stimulation of cortical neurons using externally applied, powerful, focused magnetic field pulses. rTMS consistently achieves response rates of 50-55% and remission rates of 30-35% in medically refractory MDD patients. However, the vast majority of studies have focused its use in outpatient samples. This study will address whether accelerated rTMS (intermittent Theta Burst Stimulation (iTBS)) can speed up the response rate and shorten length of stay in hospital for inpatients, and which biological traits may predict response.

Conditions

Interventions

DEVICE

repetitive transcranial magnetic stimulation (MagPro X100).

accelerated rTMS.

DEVICE

Intermittent Theta burst stimulation ( iTBS)

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Fidel Vila-Rodriguez, MD · University of British Columbia

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2018-03-01
Completion
2018-03-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628573 on ClinicalTrials.gov